Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Fleischmann

Showing results (141-150 of 160) with videos related to

Pageof 16
Sort By:
The New England Journal of Medicine|July 17, 1997
Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion proteinL W Moreland, S W Baumgartner, M H Schiff, et al.
The New England Journal of Medicine|November 30, 2000
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritisJ M Bathon, R W Martin, R M Fleischmann, et al.
Rheumatology (Oxford, England)|February 8, 2020
Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)Vinod Chandran, Désirée van der Heijde, Roy M Fleischmann, et al.
Arthritis Care & Research|October 17, 2015
Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical TrialPaul Emery, Roy M Fleischmann, Ingrid Strusberg, et al.
The Journal of Rheumatology|August 24, 2000
Treatment of rheumatoid arthritis with a DR4/1 peptideE W St Clair, S B Cohen, M L Lee, et al.
Arthritis and Rheumatism|August 1, 2009
Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritisPaul Emery, Roy M Fleischmann, Larry W Moreland, et al.
Arthritis and Rheumatism|July 13, 2002
Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomesMark C Genovese, Joan M Bathon, Richard W Martin, et al.
Journal of Clinical Pharmacology|February 27, 2007
Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritisHonghui Zhou, Haishan Jang, Roy M Fleischmann, et al.
BMJ Open|March 5, 2025
Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X)Michael E Weinblatt, Peter C Taylor, Iain B McInnes, et al.
Annals of the Rheumatic Diseases|December 16, 2018
Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritisMargreet Kloppenburg, Charles Peterfy, Ida K Haugen, et al.
Pageof 16

Showing results (141-150 of 160) with videos related to

Sort By:
Pageof 16
The New England Journal of Medicine|July 17, 1997
Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion proteinL W Moreland, S W Baumgartner, M H Schiff, et al.
The New England Journal of Medicine|November 30, 2000
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritisJ M Bathon, R W Martin, R M Fleischmann, et al.
Rheumatology (Oxford, England)|February 8, 2020
Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)Vinod Chandran, Désirée van der Heijde, Roy M Fleischmann, et al.
Arthritis Care & Research|October 17, 2015
Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical TrialPaul Emery, Roy M Fleischmann, Ingrid Strusberg, et al.
The Journal of Rheumatology|August 24, 2000
Treatment of rheumatoid arthritis with a DR4/1 peptideE W St Clair, S B Cohen, M L Lee, et al.
Arthritis and Rheumatism|August 1, 2009
Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritisPaul Emery, Roy M Fleischmann, Larry W Moreland, et al.
Arthritis and Rheumatism|July 13, 2002
Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomesMark C Genovese, Joan M Bathon, Richard W Martin, et al.
Journal of Clinical Pharmacology|February 27, 2007
Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritisHonghui Zhou, Haishan Jang, Roy M Fleischmann, et al.
BMJ Open|March 5, 2025
Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X)Michael E Weinblatt, Peter C Taylor, Iain B McInnes, et al.
Annals of the Rheumatic Diseases|December 16, 2018
Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritisMargreet Kloppenburg, Charles Peterfy, Ida K Haugen, et al.
Pageof 16